ArticleWorld journal of surgical oncology2025
eIF6: a promising therapeutic target for gastric carcinoma via PI3K/AKT pathway modulation.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundGastric carcinoma (GC) is a leading cause of cancer-related deaths, with a dire prognosis for advanced stages. The molecular mechanisms underlying GC progression are not fully understood, necessitating research into novel biomarkers and therapeutic targets. This study investigates the role of eukaryotic translation initiation factor 6 (eIF6) in GC, focusing on its potential as a prognostic indicator and its impact on tumor biology.
methodsWe analyzed eIF6 expression in GC tissues using data from TCGA and GEO databases. Experiments included western blot, IHC staining, and cell culture assays on GC cell lines to evaluate the effect of eIF6 on cell proliferation, invasion, and apoptosis. Statistical analyses were performed using Student's t-tests and ANOVA, with significance set at p < 0.05.
resultseIF6 was found to be significantly overexpressed in GC tissues, associated with advanced tumor stage and poor patient survival. Functional assays demonstrated that eIF6 knockdown inhibits GC cell proliferation and invasion while promoting apoptosis. Transcriptomic analysis linked eIF6 to the PI3K/AKT pathway, a critical regulator in cancer.
conclusionseIF6's overexpression in GC suggests its role in tumor progression, highlighting its potential as a therapeutic target. The study provides a foundation for developing targeted therapies against eIF6 and emphasizes the need for further research into its regulatory mechanisms in GC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.